Nicolas Herranz

Nicolas Herranz

Auto-generated profile, based on publicly available information

Nicolas Herranz

Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
JBJulian Brandariz
Julian Brandariz
DLDe Llobet Lara
De Llobet Lara
VEVictor Esquefa
Victor Esquefa
DADaniel Aguilar
Daniel Aguilar
ASAndrei Salca
Andrei Salca
NHNicolas Herranz
Nicolas Herranz
Metastatic prostate cancer (mPC) is a lethal disease; most therapeutic options focus on androgen receptor signaling inhibition, but resistance eventually arises. Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) have shown antitumor efficacy in mPC preclinical models, but their efficacy in mPC clinical trials has been limited. We hypothesize that novel combination therapies designed leveraging mPC adaptation to CDK4/6i could lead to increased and sustained antitumor effect. In this study, we demonstrate in a range of in vitro and in vivo prostate cancer models, including patient-derived xenografts, that prostate cancer cells adopt a senescent phenotype upon CDK4/6 inhibition that can be selectively targeted using senolytic compounds. Notably, interrupting CDK4/6 inhibition in intermittent drug schedules prompts a rapid bypass of the senescent phenotype that is associated with a temporal downregulation of replisome proteins in Rb-proficient but not in Rb-deficient models, leading to DNA damage accumulation and replication stress following treatment withdrawal. This effect opens a window of opportunity for treatment with PARP inhibitors (PARPi): Although upfront combined inhibition of CDK4/6 and PARP1 had no antitumor effect, their sequential use adding PARPi upon CDK4/6i withdrawal and cell-cycle reentry results in major antitumor activity. Our findings underscore the potential of CDK4/6i in prostate cancer therapy, particularly when administered under biology-driven sequential use of senolytic therapy or PARPi. Such strategic interventions hold promise in overcoming resistance and enhancing treatment outcomes for patients with advanced prostate cancer and open avenues for repurposing CDK4/6i therapy in mPC.

2 December 2025
Verified
Other
Open access
JBJulian Brandariz
Julian Brandariz
DLDe Llobet Lara
De Llobet Lara
VEVictor Esquefa
Victor Esquefa
DADaniel Aguilar
Daniel Aguilar
ASAndrei Salca
Andrei Salca
NHNicolas Herranz
Nicolas Herranz
Senolytic index (SI) values from figure S4C-D

2 December 2025
Verified
Other
Open access
JBJulian Brandariz
Julian Brandariz
DLDe Llobet Lara
De Llobet Lara
VEVictor Esquefa
Victor Esquefa
DADaniel Aguilar
Daniel Aguilar
ASAndrei Salca
Andrei Salca
NHNicolas Herranz
Nicolas Herranz
Bubble plot analysis values for senescence signatures genes in abemaciclib- vs vehicle-treated prostate cancer cell lines

2 December 2025
Verified
Other
Open access
JBJulian Brandariz
Julian Brandariz
DLDe Llobet Lara
De Llobet Lara
VEVictor Esquefa
Victor Esquefa
DADaniel Aguilar
Daniel Aguilar
ASAndrei Salca
Andrei Salca
NHNicolas Herranz
Nicolas Herranz
Heatmap values for replisome genes in abemaciclib- vs vehicle-treated prostate cancer models

2 December 2025
Verified
Other
Open access
JBJulian Brandariz
Julian Brandariz
DLDe Llobet Lara
De Llobet Lara
VEVictor Esquefa
Victor Esquefa
DADaniel Aguilar
Daniel Aguilar
ASAndrei Salca
Andrei Salca
NHNicolas Herranz
Nicolas Herranz
Abemaciclib and palbociclib induce a senescent phenotype in PC models in vitro

2 December 2025
Verified
Other
Open access
JBJulian Brandariz
Julian Brandariz
DLDe Llobet Lara
De Llobet Lara
VEVictor Esquefa
Victor Esquefa
DADaniel Aguilar
Daniel Aguilar
ASAndrei Salca
Andrei Salca
NHNicolas Herranz
Nicolas Herranz
Bubble plot analysis values for SASP signatures genes in abemaciclib- vs vehicle-treated prostate cancer cell lines